Anti-nucleosome B Lymphocytes in Lupus

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

4 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-02-28

Study Completion Date

2015-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Lupus disease is characterized by the production of pathogenic autoantibodies, which participate in end-organ damages. The phenotype of B cells producing the pathogenic autoantibodies in lupus patients is today unknown. Antinucleosome antibodies are characteristic of lupus disease.This project proposes to detect antinucleosome B cells in lupus patients and to analyse their phenotype and their frequency.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Abnormalities of B Lymphocytes During Systemic Lupus

NCT00401141

Systemic Lupus Erythematosus

COMPLETED NA

IL-26 and Systemic Lupus Erythematosus

NCT01889641

Diagnosis of Lupus According to ACR criteriaAgreement for the Blood Sampling

TERMINATED

Catalytic Antibodies and Lupus in Martinique

NCT01157468

Systemic Lupus Erythematosus

COMPLETED

Glycosylation Analysis of Lupus Anti-DNA Antibodies (GALA)

NCT05394922

Lupus Erythematosus Disseminatus Autoimmune Diseases Chronic Disease

RECRUITING

Clinico-biological Collection to Investigate the Physiopathology of Systemic Autoimmune Diseases

NCT05251415

Lupus Erythematosus Scleroderma Myositis +2 more

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Systemic Lupus Erythematosus With or Without Clinical Activity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patient

Venous blood sampling

Intervention Type OTHER

healthy volunteers

Venous blood sampling

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Venous blood sampling

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

SLE patient : diagnostic based on ACR criteria

* SLE patient producing seric anti-nucleosome antibodies (ELISA)
* SLEDAI-2K activity score : inferior to 5 for quiescent patients, superior to 8 since at least 2 months for active patients

Exclusion Criteria

\-- Other autoimmune diseases than SLE- Induced lupus

* Treatment with corticosteroids \>10mg/d (prednisone) for quiescent patients
* Treatment with corticosteroids \>20mg/d (prednisone) for active patients
* Oral immunosuppressive treatment during the last 6 months (methotrexate, azathioprine, ciclosporine, mycophénolate mofétil) for all patients, treatment during the last year with cyclophosphamide or monoclonal antibodies (rituximab, belimumab) for pour quiescent patients
* Disease which can modify B and T lymphocyte functions: primary immune deficiencies, evolutive infections, chronic viral infection (VIH in particular), chemotherapy or neoplasm antecedent

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes